Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Ana C. Garrido-Castro (Creator)
Cristina Saura (Creator)
Romualdo Barroso-Sousa (Creator)
Hao Guo (Creator)
Eva Ciruelos (Creator)
Begoña Bermejo (Creator)
Joaquin Gavilá (Contributor)
Violeta Serra (Creator)
Aleix Prat (Contributor)
Laia Paré (Creator)
Pamela Céliz (Creator)
Patricia Villagrasa (Creator)
Yisheng Li (Contributor)
Jennifer Savoie (Creator)
Zhan Xu (Creator)
Carlos L. Arteaga (Creator)
Ian E. Krop (Creator)
David B. Solit (Creator)
Gordon B. Mills (Creator)
Lewis C. Cantley (Creator)
Eric P. Winer (Creator)
Nancy U. Lin (Creator)
Jordi Rodon (Creator)
Prat Aleix (Contributor)
Carlos L. Arteaga (Creator)
Gordon B. Mills (Creator)
Lewis C. Cantley (Creator)
Eric P. Winer (Creator)

Dataset

1 Article

1 results

2020
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Garrido-Castro, A. C., Saura, C., Barroso-Sousa, R., Guo, H., Ciruelos, E., Bermejo, B., Gavilá, J., Serra, V., Prat, A., Paré, L., Céliz, P., Villagrasa, P., Li, Y., Savoie, J., Xu, Z., Arteaga, C. L., Krop, I. E., Solit, D. B., Mills, G. B., Cantley, L. C., & 3 othersWiner, E. P., Lin, N. U. & Rodon, J., Dec 1 2020, In: Breast Cancer Research. 22, 1, 120.
Research output: Contribution to journal › Article › peer-review

Open Access
51 Scopus citations